Accelerating Medicines Partnership: Type 2 Diabetes Project

The Accelerating Medicines Partnership Type 2 Diabetes Project (AMP T2D), is a multi-sector, pre-competitive partnership among government, industry, and nonprofit organizations, the goal of which is to harness collective capabilities, scale and resources toward improving current efforts to develop new therapies for complex, heterogeneous diseases, such as diabetes and diabetic complications. This program has created a T2D Knowledge Portal, which is a database of  sophisticated genotypic and phenotypic, and epigenomic information linked to clinical data from large cohorts of diabetes patients. As of July 2019, genotypic data from over a million individuals, from 75 individual datasets and covering 180 traits related to diabetes and complications are available for querying in this database. The AMP T2D program is committed to the continued development of state of the art analytical tools and the inclusion of additional datasets of value for researchers to mine and analyze. In June 2019, the program released predictions of effector genes for T2D.

Since its launch in 2014, the AMP T2D Knowledge Portal is fast becoming the go to source for deposition of large amounts of diabetes and complications data for published studies. The data are curated and harmonized for querying alongside existing data. To accelerate this growth, in 2019 the program selected 12 additional proposals to build upon and improve the tools available on the portal and add and integrate new datasets to improve our ability to 1) develop algorithms to better predict effector genes from genetic variants for diabetes and related complications and 2) functionally validate the effect of these genes in related tissue.

The end goal of the project is to have a powerful, publicly available T2D Knowledge Portal with a progressively growing database and analytical tools for identification and validation of effective T2D drug candidates. The 5-year, $58M project has been extended until April 2020.

To read the full project plan click here.

To visit the Knowledge Portal and access data and tools, click here.

Read a program overview on the NIDDK website here.

Follow the latest development on the Knowledge Portal blog.

Results & Accomplishments:

Media:

Nature Reviews Drug Discovery (February 27, 2019): Massive NIH-industry project opens portals to target validation

Nature (May 22, 2019): Exome sequencing of 20,791 cases of type 2 diabetes and 24,440 controls

Related Resources:

NIH News Release (June 2016): Diabetes portal adds data, more powerful search tools

Accelerating Medicines Partnership expands reach, potential of type 2 diabetes engine

Press release: Accelerating Medicines Partnership Announces Awards to Advance Research in Type 2 Diabetes

AMP T2D Knowledge Portal

NIH Overview of Accelerating Medicines Partnership Type 2 Diabetes

Accelerating Medicines Partnership

Accelerating Medicines Partnership - Alzheimer's Disease

Accelerating Medicines Partnership: Rheumatoid Arthritis, Systematic Lupus Erythematosus & Related Autoimmune Disorders

Partners:

Private-Sector Partners:
American Diabetes Association*
Eli Lilly and Company*
Janssen Research and Development LLC*
Juvenile Diabetes Research Foundation*
Merck Sharp & Dohme Corp.*
Pfizer Inc.*
Sanofi US Services*

*Provided financial or in-kind support for this program.

FNIH Contact:

For additional information please contact Tania Kamphaus, Scientific Program Manager, at Tkamphaus@fnih.org or (301) 435-6247.